Skip to content

Ionis Pharmaceuticals IONS Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin98.4%-0.2pp98.3%-0.1pp98.8%+0.1pp98.9%+0.3pp98.5%-0.2pp
Operating margin-33.3%+32.6pp-40.4%+26.9pp-28.8%+17.4pp-28.2%+16.6pp-65.9%-15.8pp
Net margin-30.9%+33.0pp-40.4%+24.0pp-26.5%+18.2pp-28.4%+16.6pp-63.9%-14.3pp
EBITDA margin-32%+32.2pp-39.1%+26.6pp-27.6%+27.2pp-27%+19.7pp-64.3%-12.5pp
Returns
Return on equity-67.6%+51.0pp-70.8%+22.3pp-40%+33.3pp-59.9%+45.8pp-118.6%-20.4pp
Return on assets-10.4%+6.0pp-11.7%+3.5pp-8.4%+3.5pp-9.5%+3.5pp-16.4%-2.8pp
Return on invested capital-51%+127pp-24.2%+91.4pp-32.4%+101pp-40.7%+178pp-177.7%-19.4pp
Efficiency
Asset turnover0.3×+0.1×0.3×+0.1×0.3×0.0×0.3×0.0×0.3×0.0×
Inventory turnover+1.5×1.4×+0.3×0.6×+0.2×0.6×+0.1×0.5×+0.1×
Liquidity
Current ratio4.1×-5.6×3.8×-4.6×2.8×-6.1×2.9×-4.7×9.7×+2.3×
Quick ratio4.1×-5.5×3.8×-4.6×2.8×-6.0×2.9×-4.7×9.6×+2.3×
Cash ratio0.2×-0.8×0.5×-0.3×0.4×-0.7×0.3×-0.6×1.1×0.0×
Leverage
Debt-to-equity1.4×+1.1×+4.7×1.4×+1.1×1.3×+0.5×0.3×-0.4×
Debt-to-assets0.2×+0.1×0.7×+0.6×0.3×+0.2×0.3×+0.2×0.1×0.0×
Interest coverage-19.2×+8.6×-22.1×+5.8×-16.7×+9.4×-16.1×+6.5×-27.9×-0.6×
Per Share
Book value per share$2.98-0.6%$3.06-22.3%$3.87-13.2%$3.46+91.8%$3.00+47.1%
Valuation
Market capitalization$12.4B+159%$12.81B+132%$10.43B+78.3%$6.31B-9.0%$4.8B-23.2%
Enterprise value$12.92B+175%$14.91B+171%$10.98B+91.8%$6.81B-0.7%$4.69B-23.2%
Price / sales11.7×+5.0×13.6×+5.7×10.8×+3.5×6.7×-1.8×6.7×-1.4×
Price / book25.2×+15.2×26.2×+16.8×16.9×+8.0×10×-16.3×10.1×-11.0×
EV / sales12.2×+5.7×15.8×+8.0×11.4×+4.2×7.2×-1.2×6.5×-1.3×
Earnings yield-2.6%+6.9pp-3%+5.2pp-2.5%+3.7pp-4.3%+1.0pp-9.6%-3.4pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Ionis Pharmaceuticals's profit margins?
Ionis Pharmaceuticals (IONS) runs a 98.4% gross margin and a -33.3% operating margin, with a -30.9% net margin.
Where do Ionis Pharmaceuticals's ratios come from?
Every ratio is computed from Ionis Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.